Article Text

PDF

What is the risk of cancer in a child with hemihypertrophy?
  1. P Abraham
  1. Barnsley Hospital NHS Foundation Trust, Gawber Road, Barnsley S75 2EP, UK; philipabrahamukyahoo.co.uk

Statistics from Altmetric.com

You have a 4 year old girl with hemihyperplasia limited to the left leg in your clinic come for review. This child was originally referred to your clinic a few weeks back after her mother noticed leg length discrepancy when she bought a new pair of trousers. You notice asymmetry between the two legs, with the left leg larger and longer than the right. An orthopaedic surgeon was consulted, who ruled out a hip problem and suggested the possibility of hemihyperplasia of the left leg. There is an increased risk of cancer, especially of Wilm’s tumour in these children, and hence a paediatric surgeon was consulted. Ultrasound scan of abdomen ruled out an intra-abdominal tumour. Her parents were trained to feel their daughter’s abdomen weekly. You are unsure about the actual incidence of the risk of tumour (cancer) development and the best scheme for surveillance. Hence you decide to look at the evidence base for these answers so that the family can be counselled appropriately.

Structured clinical question

In a child with hemihyperplasia limited to the left leg [subject] what is the risk of cancer [outcome] and what is the best follow up plan [intervention] for early detection of these cancers?

Search strategy and outcome

Cochrane database

No relevant articles found.

Medline database (1996 to date and 1951 to date)

Hemi hypertrophy or hemi hyperplasia, tumours or neoplasm, follow up ultrasound scans; 11 related articles, one was relevant which was a case series analysis of screening for Wilm’s tumour in children with Beckwith-Wiedemann syndrome (BWS)/idiopathic hemihypertrophy (HH)5 (table 3).

Table 3

 Follow up and outcome of children with hemihyperplasia

PubMed

Four searches: hemi hypertrophy, hemi hyperplasia, tumours in hemihyperplasia, hemihypertrophy and review or follow up. Limits: birth to 18 years, human. Two relevant studies identified. One was excluded as there were only 12 patients in the series. The other one was a prospective multicentre study of incidence of neoplasia and review in isolated hemihyperplasia4 (table 3).

Commentary

Hemihypertrophy is also known as hemihyperplasia. The terminology hemihyperplasia seems more accurate as the pathological process involves an abnormal proliferation rather than an increase in the size of these cells.1 Asymmetric overgrowth of unknown aetiology may involve the whole of one side of the body or it may be limited in extent to one limb or a side of the face. There may be associated asymmetric hypertrophy of internal organs. The reported incidence of hemihyperplasia is 1 in 86 000 live births.3 Hemihyperplasia may be an isolated finding or it may be associated with other syndromes such as Beckwith-Wiedmann, Klippel-Trenaunay-Weber, or McCune-Albright syndromes.

Predisposition to neoplasia (cancer) in isolated hemihyperplasia is well known, but the exact risk is not well documented. Green and colleagues2 in 1993 reported that only in one third of cases of children with Wilm’s tumour and hemihyperplasia, was the hyperplasia diagnosed more than a month prior to the discovery of the tumour.

The case series by Choyke and colleagues5 concluded that children with BWS/HH may benefit from screening abdominal ultrasound scans at intervals of four months or less, but false positive screening results may lead on to unnecessary surgery and suggested a larger prospective study to determine if the benefits of screening outweigh the risk. It was difficult to draw a conclusion from this case series with regard to isolated HH alone as this case series involved a mixture of BWS and HH cases. Also the sample size, especially of the screened group, was too small.

The only multicentre prospective study looking at the risk of tumour development and follow up of children with hemihyperplasia was the one carried out by Hoyme and colleagues.4 In this study, of the total 168 children with isolated hemihyperplasia, 10 tumours developed in nine children (one child developed two tumours). Of these, six were Wilm’s tumour, two were adrenal cell carcinoma, and there was one each of hepatoblastoma and leomyosarcoma of the small bowel. Follow up protocols varied in different centres. Two children, an infant and a 5 year old, developed Wilm’s tumours at nine month and five months respectively after their previous abdominal ultrasound scan. This led the investigators to conclude that six months may be too long a screening interval, especially in early childhood.

Hence from the available evidence, the risk of tumour development in isolated hemihyperplasia is about 1 in 20 or approximately 5%. The best follow up plan on the basis of available evidence is that till the age of 6 years these children should have abdominal ultrasound scans at three monthly intervals. There is currently insufficient evidence to screen children above 6 years of age.

CLINICAL BOTTOM LINE

  • Risk of tumour development in children with isolated hemihyperplasia is 5.9%. (95% CI 2.3%–8.2%); approximately 5% or 1 in 20. (grade A)

  • The best follow up plan for these children is to do abdominal ultrasound scans at three monthly intervals until the age of 6 years. (grade C)

  • Further clinical trials are needed to find the benefit of screening children older than 6 years of age as there is currently insufficient evidence to justify screening these children.

REFERENCES

View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.